每经记者｜赵李南 每经编辑｜文多 4月6日，钟南山在厦门大学100周年校庆活动上作了主题为《新冠防控策略与疫苗研发》的讲座。他呼吁，应当坚决接种疫苗。 钟南山表示，目前我国新冠疫苗接种比例只有百分之九点几。他认为，接种疫苗是应对接下来的经济开放的必然要求。 此外，钟南山认为，病毒的变异也给接下来的防疫工作带来了挑战，一方面毒株的变异会导致疫苗失效，另外一方面，病毒变异也影响抗体治疗的效果。 呼吁坚决接种疫苗 "中国是多少呢？只有百分之九点多（接种疫苗比例）。太低了，为什么这么低呢？两个原因，一是很多中国人觉得有什么必要接种疫苗？觉得很安全，根 本没有必要；另外一个担心有副作用。但实际上，假如大家想象一下，所有国家都接种了疫苗，你将来再开放的话，中国绝大部分人是无免疫状态，那这时 候很容易传进来，中国（将）会又暴发，那不得了。所以我们在接种疫苗这方面应该非常坚决。"钟南山表示。 病毒的变异带来挑战 "到现在为止，没有人知道这几个疫苗能够持续有效多长时间，都是未知数。"钟南山说道，给疫苗有效时间带来不确定的最大因素，就是病毒正在发生变 异。 钟南山讲座PPT（1） 图片来源：每经记者 赵李南 摄 钟南山讲座PPT ...

每经记者｜陈星 实习生 范芊芊 每经编辑｜文多 4月10日，2021全国疫苗与健康大会在成都召开。国家卫生健康委医药卫生科技发展研究中心主任、国 务院联防联控机制科研攻关组疫苗研发工作组组长郑忠伟参与了"由新冠疫苗看中国疫苗创新"为主题的 圆桌访谈。他表示，对于中国疫苗研发，在坚定自信的同时，也要了解不足。 "从此次新冠疫苗研发来看，我们所有的中国人既要有中国自信，也要有中国冷静。"他说。 封面图片来源：摄图网 他指出，在生物医药领域，我国有一些国家优势，包括体制、组织、文化优势；而不足则体现在基础研 究、载体平台、组织研发等方面，尤其在国际临床项目上与国外差距明显。 那么国际临床项目上的差距如何补足？他说，"十四五"期间，国家大概要投入40亿元左右用于推进病原 学和免疫技术体系方面的研发项目。其次，重大传染病专项培养技术也会在"十四五"期间尽早投入。另 外，目前一些疫苗方面的突破得益于企业的储备。 ...

每经记者｜王帆 每经编辑｜魏官红 自5月21日起陆续报告本土新增病例开始，广州疫情反弹正引起全国关注。5月27日17点30分，广州市政 府召开新闻发布会，通报最新情况。 广州市疾控中心副主任张周斌表示，本次广州疫情有两个特点，一是主要是通过共同居住、共同就餐、 共同托管等相对密闭的场合受到感染后造成的传播，感染者之间有明确的传播链条；二是病毒传播速度 非常快，传播力很强。 "病毒传播速度快，这是我们这次疫情和以往疫情一个最大的不同，病毒可以通过一起吃饭，或者是短 暂的非直接接触，就可以造成传播。"张周斌说道。 根据这些特点，张周斌给予了以下疫情防控的建议： 首先是继续做好个人防护和健康监测，如果自己或家人朋友出现了发热、干咳、乏力、咽痛、味觉减 退、腹泻等症状，要第一时间去医院就诊；其次是要有序预约接种新冠疫苗。 "近期受到疫情影响，广州市民疫苗接种的意愿空前高涨，预约人数激增，很多市民反映预约不到，有 的直接跑到接种点去排队，造成了大量的人员聚集，这样既辛苦也不利于疫情的防控。"张周斌说 道，"广东省对于广州市的疫苗供应都是给予优先保障，所以疫苗的供应不需要过度担心，大家最终一 定都会接种上新冠疫苗的，请大 ...

本报（chinatimes.net.cn）记者郭怡琳 于娜 北京报道 纳斯达克的一纸退市函，对已停牌六年的科兴生物下达了最后通牒，其美股上市地位命悬一线。 因未按期提交2024年年度报告，科兴生物（NASDAQ：SVA）于2025年11月12日收到纳斯达克上市资格 部门的退市决定函。若未能在规定时间内申请听证，公司股票将于11月21日起暂停交易并启动退市程 序。 这是自2019年因治理问题被停牌后，科兴生物面临的第二次退市危机。公司回应称已聘请新审计机构 UHY LLP，并将申请听证以延缓退市流程，强调"核心业务不受影响"。 对此，香颂资本董事沈萌接受《华夏时报》记者采访时表示："在中美地缘政治风险不减、科兴疫苗业 务需求下降的前提下，公司已失去继续在美挂牌的必要，复牌机会有限。" 年报迟发触发退市机制 直至2020年，新冠疫情全球暴发，科兴生物迎来转机。其研制的新冠疫苗迅速投产，公司业绩一飞冲 天。2021年，科兴生物净利润高达84.6亿美元（约合600亿元人民币）。辉煌业绩未能化解内部矛盾， 2024年，潘爱华因职务侵占罪、挪用资金罪被判刑13年。华裔科学家李嘉强控制的强新资本在二级市场 不断买入科兴生物 ...

作为全国政治、科技与总部经济的核心，北京以 49843 亿元 GDP（接近 5 万亿）稳居亚洲第三，其底气首先来自 "首都战略定位 京津冀协同" 的双重红利。 这里聚集了超 100 家央企总部，仅中石油、国家电网等企业的年度营收总和就占北京 GDP 的 35%；中关村示范区的科技企业贡献了全市 60% 的发明专利， 华为北京研究院主导的 5G 通信专利，直接支撑了全国数字经济的底层技术。大兴机场年旅客吞吐量突破 7000 万人次，加上 "轨道上的京津冀" 高铁网，让 北京的资源辐射力覆盖整个华北 —— 这种 "总部集群 科技枢纽" 的模式，既巩固了其经济量级，也让它成为亚洲高端产业的 "定盘星"。 当亚洲城市的经济版图在政策与区位的双重推力下持续重构，最新出炉的亚洲 20 强城市 GDP 排名，正藏着区域竞争的新逻辑：东京以 6.68 万亿稳居榜 首，中国城市占据半壁江山，而北京近 5 万亿的体量、苏州与香港的 "贴身追赶"、武汉在中部的突围，更成了这场洗牌里的焦点 —— 这些城市的增长内 核，到底藏着怎样的发展密码？ | 排名 | 城市 > | GDP(亿元) 国家 | | | --- | --- | -- ...

据了解，周二当天，辉瑞与其他八家机构一同启动投资级债券发行融资。此前一日，受亚马逊 (AMZN.US)150亿美元投资级债券发行推动，市场完成了263亿美元的融资交易。 这家新冠疫苗研发企业经过激烈竞标，最终以最高100亿美元的对价完成对Metsera的收购，其中包含与 或有价值权利挂钩的每股20.65美元现金额外付款。 知情人士表示，此次债券募集资金还将用于一般企业运营，并为辉瑞现有债务进行再融资。 据知情人士透露，辉瑞(PFE.US)正计划通过发行美元公司债券募集至少50亿美元资金，部分用于资助近 期对肥胖症药物研发公司Metsera的收购交易。 这家总部位于纽约的制药巨头拟将债券分为最多七个批次发行。知情人士透露，其中期限最长的40年期 债券初步定价较美国国债收益率溢价约1.25个百分点。 ...

Core Viewpoint - Shah Capital, the second-largest shareholder of Novavax, is urging the biotechnology company to make strategic adjustments, including a potential sale, due to dissatisfaction with the weak sales of its COVID-19 vaccine [1] Group 1: Shareholder Actions - Shah Capital has increased its stake in Novavax from 7.2% in October to approximately 8.3% [1] - The shareholder has warned that if there is no progress within the next four months, it may initiate a proxy fight [1]

Core Viewpoint - The global vaccine industry is undergoing a significant adjustment, with major players experiencing a collective decline in vaccine business due to various macro factors, including a growing public skepticism towards vaccines in the U.S. [2][3][7] Group 1: Financial Performance of Major Vaccine Companies - The latest Q3 financial reports from major vaccine companies, including Sanofi, Merck, Pfizer, and GSK, indicate a downturn in vaccine sales, with a projected 19% decline in total sales for the top ten vaccines in 2024 compared to 2023, amounting to $38.4 billion [4][6]. - Sanofi reported a 17% decline in sales of COVID-19 and flu vaccines, with traditional vaccine revenue dropping 8% to €3.36 billion, primarily due to a slowdown in flu vaccine sales [4]. - Merck's sales of its HPV vaccine Gardasil/GARDASIL 9 fell by 24% to $1.75 billion in Q3, with a staggering 40% drop in revenue for the first three quarters of the year [5]. - Pfizer's COVID-19 vaccine Comirnaty saw a 20% global sales decline, with a 25% drop in the U.S. market, alongside disappointing performances from its pneumonia and RSV vaccines [5][6]. Group 2: Macro Factors Impacting Vaccine Trust - The decline in vaccine trust in the U.S. is attributed to the actions of Robert F. Kennedy Jr., the new Secretary of Health and Human Services, who has promoted anti-vaccine sentiments and policies that undermine public confidence in vaccines [7][8]. - A recent survey indicated that 30% of Americans are skeptical about vaccines, with a significant drop in the belief that childhood vaccines are essential, from 58% in 2019 to 40% in 2024 [8]. - The CDC reported over 1,600 confirmed measles cases in 2025, a stark increase from 285 cases the previous year, highlighting the consequences of declining vaccination rates [9]. Group 3: Historical Context and Future Implications - The current situation in the U.S. vaccine market mirrors Japan's past vaccine industry decline, which was triggered by public trust issues and government policy changes that led to a significant drop in vaccination rates [10][11]. - The ongoing crisis in vaccine trust poses a risk not only to the industry but also to public health, as evidenced by the resurgence of preventable diseases like measles [9][10].

Core Viewpoint - Moderna's stock surged over 11% in pre-market trading following the release of its third-quarter earnings report, despite a significant year-over-year revenue decline [1] Financial Performance - Revenue for the third quarter was reported at $1.02 billion, a 45% decrease compared to the previous year, but it exceeded analyst expectations of $879.6 million [1] - Sales from COVID-19 vaccines reached $971 million during the quarter, which included $781 million in sales from the U.S. and $190 million from international markets [1] - The company recorded a net loss of $200 million, translating to a loss of $0.51 per share, which was significantly better than the analyst forecast of a loss of $2.11 per share [1]

Core Insights - Joel Mokyr, along with Philippe Aghion and Peter Howitt, was awarded the 2025 Nobel Prize in Economic Sciences for their contributions to the theory of innovation-driven economic growth, with Mokyr receiving half of the prize for revealing the prerequisites for sustained growth through technological advancement [1][3]. Group 1: Innovation and Economic Growth - The core premise for sustained economic growth is "useful knowledge," which consists of prescriptive knowledge (how to operate technology) and propositional knowledge (understanding the scientific principles behind technology) [4][5]. - The Industrial Revolution marked the first strong feedback loop between these two types of knowledge, laying the foundation for modern economic growth [5]. Group 2: Importance of Understanding Principles - Understanding the principles behind technology is crucial for sustainable innovation; merely knowing how to do something is insufficient [6][8]. - Historical examples, such as the development of agricultural practices and steam engines, illustrate that scientific understanding leads to significant advancements and efficiency improvements [7][8]. Group 3: Measurement of Productivity - Current economic growth rates may not accurately reflect productivity due to outdated measurement methods that fail to account for non-market goods and services that enhance human welfare, such as vaccines [9]. - There is a need for new methods to measure productivity that align with modern economies focused on information and advanced services [9]. Group 4: Openness and Collaboration - For an economy to thrive, it must remain open to trade, talent, and knowledge exchange, emphasizing the importance of a free market for ideas and knowledge [10]. - Collaboration between the public and private sectors is essential for fostering innovation, with the balance depending on industry characteristics [10]. Group 5: China's Investment in Education and Infrastructure - China's significant investments in infrastructure and higher education are expected to yield substantial returns for its economy [11]. - The relationship between state-owned and private enterprises needs to be recalibrated to foster innovation effectively [11]. Group 6: Historical Perspective on Economic Progress - Economic history provides valuable insights into the progress made over time, highlighting that current living standards are unprecedented compared to historical norms [14][15]. - Understanding economic history is essential for comprehending modern economic systems and challenges [14]. Group 7: Lifelong Learning - Young individuals are encouraged to maintain a habit of lifelong learning to adapt to the rapidly changing world, as knowledge becomes outdated quickly [16][17].